Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial
Obesity · 2025-09 · 33 (9) · 1645-1656
DOI: 10.1002/oby.24332 ↗At a glance
Journal article in Obesity, published online on 2025-06-22. Written by Carolyn S P Lam and 19 co-authors. Institution: Cardiovascular and Metabolic Disorders Programme, Duke-National University of Singapore Medical School, Singapore, Singapore. Major MEDLINE topics: Obesity, Cardiovascular Diseases, Tirzepatide. Cited 48 times so far (Crossref); 51 references. Funded by: Eli Lilly and Company.
Abstract (original language)
Objective
Obesity is a major cause of morbidity and mortality worldwide. Tirzepatide is a glucose‐dependent insulinotropic polypeptide receptor and glucagon‐like peptide‐1 receptor agonist providing substantial weight reduction and metabolic benefits both in type 2 diabetes and obesity. We hypothesized that tirzepatide can improve morbidity and mortality in adults with obesity or overweight but without diabetes.
Methods
SURMOUNT‐MMO is a randomized, double‐blind, event‐driven trial to investigate the impact on morbidity and mortality with once‐weekly tirzepatide compared with placebo in adults living with obesity, without diabetes, and with, or at risk of, cardiovascular disease. The primary endpoint is time to first occurrence of a five‐component composite outcome of nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, heart failure events, or death from any cause.
Results
The trial will enroll ~15,000 participants aged ≥40 from 664 sites across 27 countries with BMI ≥27.0 kg/m 2 and either established cardiovascular disease or multiple cardiovascular risk factors.
Conclusions
SURMOUNT‐MMO will provide evidence of the clinical benefits of tirzepatide on multiple outcomes among individuals with overweight or obesity but without diabetes. This is the first outcome trial of an incretin medication that assesses both primary and secondary cardiovascular disease prevention.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Cardiovascular and Metabolic Disorders Programme, Duke-National University of Singapore Medical School, Singapore, Singapore.
- National Heart Centre Singapore, Singapore, Singapore.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
- Endocrinology and Metabolic Diseases, CNR Institute of Clinical Physiology, Pisa, Italy.
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
ORCID profiles: Carolyn S P Lam, Ania M Jastreboff
Funding
- Eli Lilly and Company
Cite
APA
Lam, C. S. P., Rodriguez, A., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., Sanyal, A. J., Yki-Jarvinen, H., Mason, D., Strzelecki, M., Bartee, A. K., Cui, C., Hurt, K., Linetzky, B., Bunck, M. C., & Nissen, S. E. (2025). Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial. Obesity, 33(9), 1645-1656. https://doi.org/10.1002/oby.24332
Vancouver
Lam CSP, Rodriguez A, Aminian A, Ferrannini E, Heerspink HJL, Jastreboff AM, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial. Obesity. 2025;33(9):1645-1656. doi:10.1002/oby.24332
BibTeX
@article{Lam2025,
author = {Lam, Carolyn S P and Rodriguez, Angel and Aminian, Ali and Ferrannini, Ele and Heerspink, Hiddo J L and Jastreboff, Ania M and Laffin, Luke J and Pandey, Ambarish and Ray, Kausik K and Ridker, Paul M and Sanyal, Arun J and Yki-Jarvinen, Hannele and Mason, Denise and Strzelecki, Michelle and Bartee, Amy K and Cui, Can and Hurt, Karla and Linetzky, Bruno and Bunck, Mathijs C and Nissen, Steven E},
title = {Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial},
journal = {Obesity},
year = {2025},
volume = {33},
number = {9},
pages = {1645--1656},
doi = {10.1002/oby.24332}
}
EUVIMED